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Protocol
AbstrACt
Introduction Chronic pelvic pain (CPP) affects more than 
1 million UK women with associated healthcare costs 
of £158 million annually. Current evidence supporting 
interventions when no underlying pathology is identified 
is very limited and treatment is frequently inadequate. 
Gabapentin (a GABA analogue) is efficacious and often 
well tolerated in other chronic pain conditions. We have 
completed a successful pilot randomised controlled trial 
Gabapentin for Pelvic Pain 1 (GaPP1) and here describe 
the protocol for our definitive multicentre trial to assess 
the efficacy of gabapentin in the management of CPP in 
women Gabapentin for Pelvic Pain 2 (GaPP2).
Methods and analysis We plan to perform a double-
blind placebo-controlled randomised multicentre clinical 
trial, recruiting 300 women with CPP from up to 40 
National Health Service hospitals within the UK. After 
randomisation, women will titrate their medication 
(gabapentin or placebo) over a 4-week period to a 
maximum of 2700 mg or placebo equivalent and will then 
maintain a stable dose for a 12-week period. Response to 
treatment will be monitored with validated questionnaires 
and coprimary outcome measures of average and worst 
pain scores will be employed. The primary objective is to 
test the hypothesis that treatment with gabapentin has the 
potential to provide an effective oral treatment to alleviate 
pain in women with CPP in the absence of any obvious 
pelvic pathology.
Ethics and dissemination Ethical approval has been 
obtained from the Coventry and Warwick Research Ethics 
Committee (REC 15/WM/0036). Data will be presented at 
international conferences and published in peer-reviewed 
journals. We will make the information obtained from the 
study available to the public through national bodies and 
charities.
trial registration number ISRCTN77451762; Pre-results.
IntroduCtIon 
Chronic pelvic pain (CPP) affects more than 
1 million women in the UK.1–3 It is associated 
with significantly reduced quality of life 
(QoL),4 5 a 45% reduction in work produc-
tivity and it has been estimated that caring for 
women with CPP in the UK costs £158 million 
annually.6 7 CPP can be associated with under-
lying pathology such as endometriosis, but in 
up to 55% of women no obvious cause can 
be identified at laparoscopy.6 Management of 
CPP is difficult when no pathology is identi-
fied, as no established gynaecological treat-
ments are available. Due to its effectiveness 
in other chronic pain conditions, gabapentin 
(a GABA analogue), is increasingly being 
prescribed for CPP in both primary and 
secondary care.8 However, there is no good 
quality evidence in CPP specifically on which 
to base this practice.9 To our knowledge, 
there is only one study evaluating the use of 
gabapentin for CPP, which did not have a 
placebo arm.10 This small study in 56 women, 
compared gabapentin with amitriptyline and 
showed gabapentin to have greater efficacy at 
improving pain scores at 12 months. However, 
efficacy of gabapentin has been proven in 
other chronic pain conditions. A recent high-
quality review showed the number needed to 
treat to be 5.8 (95% CI 4.3 to 9.0) to achieve at 
least 50% pain intensity reduction in painful 
diabetic neuropathy (829 patients); 7.5 (95% 
CI 5.2 to 14) to achieve at least 50% pain 
intensity reduction in postherpetic neuralgia 
(892 patients) and 5.4 (95% CI 2.9 to 31) to 
achieve at least 30% pain intensity reduction 
in fibromyalgia (150 patients).8 Moreover, it 
is a drug that is very well tolerated: all-cause 
withdrawal rates are similar to placebo 
(gabapentin: 20%; placebo: 19%; number of 
studies: 17; number of participants: 3063).8 
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Given the clinical need for a medical treatment for 
CPP with no identifiable underlying pathology and the 
strong evidence supporting the acceptability and effi-
cacy of gabapentin in other chronic pain conditions, we 
considered that further investigation of gabapentin as a 
potential treatment for CPP in women was warranted. 
We hypothesise that treatment of women with CPP in the 
absence of any obvious pelvic pathology with gabapentin 
will alleviate pain and improve physical and emotional 
functioning. We initially performed a successful pilot 
randomised controlled trial (RCT) (GaPP1).11 12 Here, 
we describe the protocol for our definitive multicentre 
trial to assess the efficacy of gabapentin in the manage-
ment of CPP in women (GaPP2).
objectives
Primary objective
The primary objective is to test the hypothesis that treat-
ment with gabapentin has the potential to provide an 
effective oral treatment to alleviate pain in women with 
CPP in the absence of any obvious pelvic pathology.
Secondary objective
The secondary objective is to test the hypothesis that 
treatment with gabapentin has the potential to improve 
physical and emotional functioning in women with CPP 
in the absence of any obvious pelvic pathology.
outcomes
Primary outcome
We will employ coprimary outcome measures of average 
and worst pain scores recorded on a Numerical Rating 
Scale (NRS). To capture the cyclicity that may occur with 
CPP, weekly pain scores (on a 0–10 scale) will be recorded 
during the final 4 weeks of treatment (weeks 13–16 
postrandomisation), in the form of: (1) ‘average pain this 
week’ and (2) ‘worst pain this week’.
The composite ‘average’ pain score will be taken as the 
average of the four weekly average pain scores submitted, 
and the composite ‘worst’ pain score as the worst of the 
four weekly worst pain scores submitted.
Secondary outcomes
 ► Physical and emotional function and QoL.
 ► Satisfaction with treatment.
 ► Patient estimate of whether on active treatment or 
on placebo group, and confidence in and reasons for 
estimate.
 ► Adherence to trial treatments, as reported by the 
participants.
 ► Concomitant analgesic use, as reported by the 
participants.
 ► Adverse events, as reported by participants (prin-
cipally those that are serious and detailed in the 
summary of product characteristics and those that are 
unexpected).
 ► General practitioner/hospital consultations, as 
reported by the participants.
 ► Time off work and ‘presenteeism’.
MEthods And AnAlysIs
study design
GaPP2 is a double-blind placebo-controlled randomised 
multicentre clinical trial (figure 1). We will screen women 
with CPP from up to 40 National Health Service hospi-
tals within the UK. Women will return weekly NRS pain 
scores to the trials office for 4 weeks after initial consent. 
Those women meeting the inclusion criteria at the end of 
these 4 weeks will be randomised. We will randomise 300 
women (150 to gabapentin, 150 to placebo). After rando-
misation and titration, participants will receive treatment 
with the maximum tolerated dose for 12 weeks. Partici-
pants and the healthcare team will be unblinded at the 
end of their treatment.
Participants
A total of 300 women with a history of CPP with no obvious 
pelvic pathology detected at laparoscopy will be recruited 
to the trial.
Inclusion criteria
 ► Women aged between 18 and 50 years.
 ► CPP (with or without dysmenorrhoea or dyspareunia) 
of >3-months duration.
 ► Pain located within the true pelvis or between and 
below anterior iliac crests.
 ► No obvious pelvic pathology at laparoscopy (laparos-
copy must have taken place at least 2 weeks ago, but 
no more than 36 months prior to screening).
 ► Using or willing to use effective contraception if 
necessary to avoid pregnancy.
 ► Able to give informed consent.
 ► For both the worst and average prerandomisation 
NRS questions, at least three of the four weekly scores 
returned to the trials office. At least two of the worst 
pain scores should be ≥4/10. Potential participants 
who have been on a stable dose of an analgesic, other 
than gabapentin or pregabalin, for at least 4 weeks 
prior to screening will be eligible.
Exclusion criteria
 ► Dysmenorrhoea alone
 ► known pelvic pathology:
 – endometriosis (macroscopic lesions)
 – complex or >5 cm ovarian cyst
 – fibroid >3 cm
 – dense adhesions
 ► current malignancy under treatment
 ► current use of gabapentin/pregabalin
 ► taking Gonadotrophin Releasing Hormone (GnRH) 
agonists and unable/unwilling to stop
 ► surgery planned in the next 6 months
 ► history of significant renal impairment
 ► previous allergic reaction to gabapentin
 ► breast feeding
 ► pregnant
 ► planning pregnancy in next 6 months
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Figure 1 Study flow chart. AE, adverse event; NRS, Numerical Rating Scale; PROM, patient-reported outcome measure.
group.bmj.com on February 23, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Vincent K, et al. BMJ Open 2018;8:e014924. doi:10.1136/bmjopen-2016-014924
Open Access 
 ► pain suspected to be of gastrointestinal origin (posi-
tive Rome III Diagnostic Criteria)
 ► coenrolment in another Clinical Trial of an Investiga-
tional Medicinal Product.
Participant enrolment
Research nurses (dedicated or through the National Insti-
tute for Health Research’s Clinical Research Network, 
depending on the site) will be employed for the duration 
of the study to approach eligible women, provide them 
with patient information sheets and offer them the oppor-
tunity to discuss the trial, and obtain informed consent 
for screening. Consent will only be taken once the patient 
has had ample time to read the patient information sheet 
and had her questions answered.
study settings
We will recruit patients from gynaecology outpatient 
clinics, gynaecology wards and day surgery units and CPP 
clinics within the UK.
Intervention and randomisation
Randomisation to gabapentin or placebo will occur 
once written informed consent has been obtained, final 
eligibility established from the pain responses provided 
during the screening phase and baseline questionnaires 
completed. The Birmingham Clinical Trials Unit (BCTU) 
will provide third-party web-based randomisation with 
telephone backup. A minimisation procedure using a 
computer-based algorithm will be used to avoid chance 
imbalances in treatment allocation and the following 
potentially important variables:
1. presence or absence of dysmenorrhoea (a pain score 
of ≥4/10 will be considered significant);
2. psychological distress measured by the General Health 
Questionnaire (GHQ) (scored as 0–12 with a cut-off 
of 0–1 and 2–12 for minimisation);
3. use of sex hormonal treatments (combined oral con-
traceptive, progestogens, levonorgestrel-releasing in-
trauterine system (Mirena));
4. centre.
A ‘random element’ will be included in the minimi-
sation algorithm, so that each patient has a probability 
(unspecified here) of being randomised to the oppo-
site treatment that they would have otherwise received. 
Full details of the algorithm used will be stored in a 
confidential document at BCTU. Both participants 
and the research team will remain blind to allocation.
dose regimen
After randomisation, participants will be allocated 
a trial treatment pack from the hospital pharmacy 
containing either gabapentin or placebo oral tablets, 
both of identical appearance. Participants will start on 
one capsule (300 mg) daily and will increase by one 
capsule (300 mg) increments every 3 days until they 
perceive that they are gaining adequate pain relief, 
or report side effects (eg, dizziness, somnolence, 
mood changes, appetite and poor concentration) 
that preclude them from further increases, up to a 
maximum dose of nine capsules (2700 mg), as shown 
in table 1. The titration phase will last a maximum of 4 
weeks. If necessary they will be advised to titrate down 
to the last tolerated dose with minimal side effects. 
They will be asked to maintain their best tolerated 
dose until the end of week 16. Patients will be advised 
and given written instructions regarding their dosing 
regimen by a member of the research team. It will be 
recommended that the drug should be taken in three 
equally divided doses daily. The same protocol will 
be used for the placebo. When the participant stops 
treatment, the dose will be reduced according to a 
dose reduction chart and written instructions will be 
given. Patients will be allowed to use other medication 
(including analgesics, self-medication and alternative 
treatments, eg, acupuncture) throughout the study 
period.
data collection
Data storage
All the data generated from the study will be stored in 
a bespoke database, which will be password protected. 
All paperwork will be kept in a locked filing cabinet in 
a locked office. All data will be stored in accordance 
with the Data Protection Act.
Screening
A member of the research team will assess the woman 
for eligibility to enter the screening phase. All data will 
be recorded on a case report form (CRF) and trans-
ferred to a secure database, which will trigger the start 
of the weekly collection of pain scores.
Participant log
The clinical research team will keep an anonymised 
electronic log of women who fulfil the eligibility 
criteria, women who are invited to participate in the 
study, women recruited and women who leave the trial 
early. Reasons for non-recruitment (eg, non-eligibility, 
refusal to participate and administrative error) will 
also be recorded. During the course of the study, we 
will document reasons for withdrawal from the study 
and lost to follow-up if available.
Pain scores
Pain NRS will be collected by an automated text 
messaging system. Two texts will be sent to the women’s 
mobile phone, asking about average and worst pain, 
respectively, and the woman will be asked to reply to the 
text message with her pain score, rating it from 0 (for 
no pain at all) to 10 (being worst pain imaginable). To 
capture cyclicity, these will be collected weekly during 
the eligibility phase (weeks −1 to −4) and during the 
last 4 weeks of the treatment phase (weeks 13–16).
Treatment diaries
Participants will be provided with a treatment diary at 
the same time as their medication pack is dispensed. 
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The following measures will be completed by the 
participant daily from day 1 of treatment until week 16:
 ► dose of gabapentin taken
 ► reason for any change in trial medication dose
 ► alternative therapies used
 ► any visits to a healthcare professional.
Questionnaires
A questionnaire will be given to all participants before 
randomisation but after screening (baseline) and at 16 
weeks postrandomisation (see table 2 for full schedule 
of assessments). This will include the following vali-
dated tools:
 ► 12-Item Short-Form Health Survey (SF-12): a QoL 
measure.13
 ► Brief Pain Inventory (BPI)14: a tool to measure pain 
intensity and interference of pain in a patient’s life.
 ► Brief Fatigue Inventory (BFI).15
 ► GHQ16: to identify psychological distress.
 ► Work and Productivity Activity Impairment 
Questionnaire (WPAIQ).17
 ► Pain Catastrophising Scale (PCS).18
 ► Sexual Activity Questionnaire (SAQ).19
 ► PainDETECT: to identify a neuropathic component 
to pain.20
 ► Pelvic Pain and Urinary/Frequency Patient Symptom 
Scale (PUF) (at baseline only).
The questionnaire at baseline will include questions 
to capture the baseline demographic and clinical char-
acteristics of the participants.
Table 1 Dose escalation schedule for GaPP2
Day in study
Total number of 
capsules/day
(maximum) Dosing
Maximum daily dose 
of gabapentin (mg)
1 1 One capsule night 300
2 1 One capsule night 300
3 1 One capsule night 300
4 2 One capsule two times a day 600
5 2 One capsule two times a day 600
6 2 One capsule two times a day 600
7 3 One capsule three times a day 900
8 3 One capsule three times a day 900
9 3 One capsule three times a day 900
10 4 One capsule two times+two capsules at night 1200
11 4 One capsule two times+two capsules at night 1200
12 4 One capsule two times+two capsules at night 1200
13 5 Two capsules two times+one capsule once 1500
14 5 Two capsules two times+one capsule once 1500
15 5 Two capsules two times+one capsule once 1500
16 6 Two capsules three times a day 1800
17 6 Two capsules three times a day 1800
18 6 Two capsules three times a day 1800
19 7 Two capsules two times+three capsules night 2100
20 7 Two capsules two times+three capsules night 2100
21 7 Two capsules two times+three capsules night 2100
22 8 Three capsules two times+two capsules once 2400
23 8 Three capsules two times+two capsules once 2400
24 8 Three capsules two times+two capsules once 2400
25 9 Three capsules three times a day 2700
26 9 Three capsules three times a day 2700
27 9 Three capsules three times a day 2700
28–112 Remain on maximum tolerated dose until the end of week 16 (not exceeding 2700 mg or nine capsules 
per day). Daily dose should be divided equally into three doses.
GaPP2, Gabapentin for Pelvic Pain 2.
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All questionnaires will be anonymised and completed 
in private.
Adverse events
Participants will collect information about adverse 
events in their treatment diaries. However, they will be 
instructed to contact the clinical research team at any 
time after consenting to join the trial if they have an 
event that requires hospitalisation or an event that results 
in persistent or significant disability or incapacity. Any 
serious adverse events (SAEs) that occur after joining the 
trial will be reported in detail in the participant’s medical 
notes and followed up until resolution of the event. The 
assessment of seriousness, causality and expectedness 
will be conducted assuming that the participant received 
gabapentin, with the blinding not broken. All SAEs will 
be reported to the Academic and Clinical Central Office 
for Research and Development (ACCORD) Research 
Governance (http://www. accord. ed. ac. uk) and Quality 
Assurance Office based at the University of Edinburgh 
immediately or within 24 hours. ACCORD will onward 
report all SAEs to BCTU within 7 days.
Termination of study
Participants will be unblinded at the end of the study and 
if taking gabapentin will have the option to continue on 
treatment or will be tapered off treatment. Participants 
who have been on placebo will be given the choice to start 
on gabapentin, which will be prescribed by their clinician. 
Participants will be given an emergency contact card to 
carry while participating in the study. The blinding code 
will only be broken in emergency situations for reasons of 
patient safety, where knowledge of the treatment adminis-
tered is necessary for the treatment of a SAE. Participants 
whose randomisation codes are broken will cease treat-
ment with the study drug, but will continue to be followed 
up. Participants may discontinue from the trial at any 
time at their own request, or they may be withdrawn at 
any time at the discretion of the research team for safety, 
behavioural or administrative reasons. Data collection is 
envisaged to be complete in September 2018.
sample size
We have based our sample size on being able to detect 
a minimally important difference (MID) in NRS scores 
with high levels of power. Studies have shown the MID in 
this population to be around 1 point on a 0–10 scale.21 
Our pilot study showed worst and average pain scores to 
have SDs between 2.0 and 2.5. If the SD is at the lower 
end of these estimates, 86 patients in each group (172 in 
total) would be required to have 90% power (P=0.05) to 
detect a difference of 1 point. If the SD is at the higher 
end, we could detect the same difference with 80% 
power (P=0.05) with 100 patients in each group. We have 
assumed the latter SD (2.5) to be conservative. To account 
for any increase in the risk of type I error that may be asso-
ciated with having coprimary outcome measures, we have 
Table 2 Schedule of outcome assessments for GaPP2
Phase Run-in
Baseline, 
randomisation 
and treatment 
dispensed Titration Treatment
End of study 
and unblinding Taper
Duration (weeks) −4 to −1 0 1–4 5–12 13–16 17–19
Weekly worst and 
average NRS
x x x x x x x x
SF-12 X X
BPI X X
PCS X X
SAQ X X
BFI X X
GHQ X X
WPAIQ X X
PainDETECT X X
PUF X
Adverse events X X X X X
Permitted/concomitant 
medication
X X X X X
Adherence or 
discontinuation
X X X X
BFI, Brief Fatigue Inventory; BPI, Brief Pain Inventory; GHQ, General Health Questionnaire; NRS, Numerical Rating Scale; PCS, Pain 
Catastrophising Scale; PUF, Pelvic Pain and Urinary/Frequency Patient Symptom Scale; SAQ, Sexual Activity Questionnaire; SF-12, 12-Item 
Short-Form Health Survey; WPAIQ, Work and Productivity Activity Impairment Questionnaire.
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applied a Bonferroni correction (alpha reduced to 0.025 
from 0.05), which increases the sample size to 120 per 
group. Furthermore, to account for an expected average 
20% lost to follow up, we will randomise 150 per group, 
300 patients in total.
Proposed analyses
Data analysis will be by intention to treat. Every attempt 
will be made to gather data on all women randomised, 
irrespective of compliance with the treatment protocol. 
Appropriate baseline characteristics, split by treatment 
group, will be presented for each outcome. Point esti-
mates, 95% CIs and P values from two-sided tests will be 
reported.
Primary analysis
We will use a linear regression model to estimate differ-
ences in worst and average NRS scores between the two 
treatment groups, including baseline score and the mini-
misation variables as covariates. The P value from the 
associated χ2 test will be produced and used to deter-
mine statistical significance. A Bonferroni correction will 
be applied as there are two primary outcomes. Further 
analysis using a repeated measures (multilevel) model 
will also be performed incorporating all eight recorded 
scores.
Secondary analysis
Data from the other continuous measures (SF-12, BPI, 
PCS, SAQ, WPAIQ, BFI, PainDETECT and GHQ) will 
be analysed in a similar manner to the primary measure. 
Other outcome measures (use of permitted analgesic 
medication, satisfaction) will be analysed using standard 
methods (tests for trend, absolute/relative risks). Further 
analysis on pain scores will include an examination of 
the proportion of women that have a 30% and a 50% 
reduction in average and worst score from baseline as the 
outcome. A log-binomial regression model will be used 
here to generate adjusted relative risks. Subgroup anal-
yses will be limited to the same variables that were used as 
minimisation variables. Tests for statistical heterogeneity 
(eg, by including treatment group by subgroup interac-
tion parameter in the linear regression model) will be 
performed prior to any examination of effect estimate 
within subgroups. In addition, we will investigate up to 
nine clinical variables measured at baseline to determine 
whether they correlate with response to treatment. These 
will include the minimisation variables (the presence 
of dysmenorrhoea/psychological distress/current use 
of hormonal treatment) along with measures of inten-
sity and of nature of pain (eg, PainDETECT), number 
of functional systems involved (as a measure of organ 
specific versus generalised pelvic pain syndrome) and 
PUF score.
Missing data and sensitivity analyses
Every attempt will be used to collect full follow-up data 
on all women. In particular, participants will continue to 
be followed up even after protocol treatment violation. 
It is thus anticipated that missing data will be minimal. 
Patients with completely missing primary outcome data 
or with only one of four pain scores recorded will not be 
included in the primary analysis. Secondary sensitivity 
analyses will be performed to investigate the impact of 
missing data for the primary outcome: this will include 
a worst score assumption. We will also simulate missing 
responses using a multiple imputation approach.
research governance
We shall adopt the standard approach used for moni-
toring RCTs and have a Trial Steering Committee (TSC) 
of at least four independent members, including pain 
specialist, a gynaecologist, trial methodologist and 
a Patient and Public Involvement (PPI) representa-
tive. There will also be a Data Monitoring Committee 
(DMC) comprising three independent members (a 
pain specialist, a gynaecologist and a statistician with 
extensive trial experience) who will review interim anal-
yses. The terms of reference and charter for this DMC 
will be guided by the DAMOCLES project, and we antic-
ipate the DMC and TSC will meet biannually.
dIsCussIon
CPP is a major public health issue for women throughout 
the developed world.2 As with other chronic pain condi-
tions, it is associated with a marked reduction in QoL and 
significant financial costs for the woman, her family and 
society as a whole.4 5 When CPP is associated with under-
lying pathology such as endometriosis, therapies targeting 
the pathology can be initiated. However, in more than 
50% of women, no underlying cause is identified.6 For 
these women, not only is it difficult to comprehend 
and come to terms with how there can be no associated 
pathology,22 there are also no available evidence-based 
treatments to consider.
The efficacy of a number of pharmacological and inter-
ventional therapies has been investigated for other chronic 
pain syndromes. There is increasing evidence that women 
with CPP demonstrate central changes similar to those 
associated with other forms of chronic pain23 24 and thus it 
is likely that such therapies would also be effective for CPP. 
Moreover, recent work demonstrates a neuropathic compo-
nent in a significant proportion of women with CPP,25 
further supporting the investigation of drugs currently 
recommended for neuropathic pain26 in women with CPP. 
The multicentre placebo-controlled RCT described here 
aims to contribute to the evidence base by assessing the effi-
cacy of gabapentin in women with CPP with no underlying 
pathology.9 This trial is designed in line with the Initiative 
on Methods, Measurement, and Pain Assessment in Clinical 
Trials (IMMPACT) recommendations for the design of trials 
in chronic pain conditions21 27 28 and builds on a successful 
pilot study.11 12 Women with CPP were surveyed to iden-
tify whether reduction in average or worst pain was most 
important to them. As there was no clear consensus (average 
43.4%, worst 56.6%) coprimary outcomes of average and 
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worst pain scores have been chosen. We envisage the find-
ings being of relevance to both primary and secondary care 
clinicians managing women with CPP.
Author affiliations
1Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, 
UK
2Pain Management Centre, The National Hospital for Neurology and Neurosurgery, 
London, UK
3Institute of Applied Health Sciences, School of Medicine, Medical Sciences and 
Nutrition, University of Aberdeen, Aberdeen, UK
4Pelvic Pain Support Network, Poole, UK
5Faculty of Medicine, University of Southampton, Southampton, UK
6Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
7Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, 
University of Aberdeen, Aberdeen, UK
8MRC Centre for Reproductive Health, Queen’s Medical Research Institute, 
Edinburgh, UK
9Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
10Research Department of Clinical, Educational and Health Psychology, University 
College London, London, UK
Acknowledgements We gratefully acknowledge the other investigators that 
contributed to the design of the RCT: Jayna Holroyd-Leduc, Danielle Southern, Ward 
Flemons, Maeve O'Beirne, Michael Hill, Alan Forster and Deborah E White.
Contributors KV: research, contribution of original material, drafting, editing and 
approval of final manuscript; AWH, SB, RC, JD, LM, WS: research, contribution of 
original material, editing and approval of final manuscript; AB, IT, JB, YC, GJM, 
ACCW: contribution of original material, editing and approval of final manuscript.
Funding GaPP2 is funded by a grant from the NIHR/MRC Efficacy and Mechanism 
Evaluation (EME) Programme, Reference: 13/52/04.
Competing interests KV has received research funding from Pfizer 
Pharmaceuticals and Bayer HealthCare, honoraria from Bayer HealthCare and 
consultancy fees from Grünenthal GmbH. AWH receives grant funding from the NIHR 
and the Medical Research Council. AB has no competing issues as no direct funding 
from industry. AB is currently President of the British Pain Society. JB declares no 
competing interests. SB receives grant funding from NIHR and Chief Scientist Office 
Scotland. He has been a speaker at a number of conferences that have received 
funding from the pharmaceutical industry. His clinical colleagues receive industry 
support for travel and for Departmental Seminars. ACCW has received a consulting 
fee from Astellas. GJM is Chief Investigator of the British Society for Rheumatology 
(BSR) Biologics Register in Ankylosing Spondylitis. This is funded by the BSR who 
receive funds from Pfizer, AbbVie and UCB. YC receives grant funding from NIHR. RC 
has secured research funding from Allergan and is a member of Allergan’s scientific 
advisory panel. He also receives grant funding from the NIHR via UCL Biomedical 
Research Centre. IT is supported by grants from NIHR Oxford Biomedical Research 
Centre, Medical Research Council of Great Britain and Northern Ireland, the 
Wellcome Trust.
Patient consent Obtained.
Ethics approval Ethics approval has been obtained from the Coventry and 
Warwick Research Ethics Committee (REC 15/WM/0036).
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits 
others to distribute, remix, adapt and build upon this work, for commercial use, 
provided the original work is properly cited. See: http:// creativecommons. org/ 
licenses/ by/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEFErEnCEs
 1. Zondervan KT, Yudkin PL, Vessey MP, et al. Prevalence and 
incidence of chronic pelvic pain in primary care: evidence from 
a national general practice database. Br J Obstet Gynaecol 
1999;106:1149–55.
 2. Latthe P, Latthe M, Say L, et al. WHO systematic review of 
prevalence of chronic pelvic pain: a neglected reproductive health 
morbidity. BMC Public Health 2006;6:177.
 3. Donaldson L. 150 years of the Annual Report of the Chief Medical 
Officer: On the state of public health 2008. London: Department of 
Health, 2009.
 4. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in 
Europe: prevalence, impact on daily life, and treatment. Eur J Pain 
2006;10:287–333.
 5. Ayorinde AA, Macfarlane GJ, Saraswat L, et al. Chronic Pelvic 
Pain in Women: An Epidemiological Perspective. Womens Health 
2015;11:851–64.
 6. Daniels JP, Khan KS. Chronic pelvic pain in women. BMJ 
2010;341:c4834.
 7. Cheong Y, William Stones R. Chronic pelvic pain: aetiology and 
therapy. Best Pract Res Clin Obstet Gynaecol 2006;20:695–711.
 8. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for 
neuropathic pain and fibromyalgia - an overview of Cochrane 
reviews. Cochrane Database Syst Rev 2013;11:CD010567.
 9. Horne AW, Vincent K, Cregg R, et al. Is gabapentin effective 
for women with unexplained chronic pelvic pain? BMJ 
2017;358:j3520.
 10. Sator-Katzenschlager SM, Scharbert G, Kress HG, et al. Chronic 
pelvic pain treated with gabapentin and amitriptyline: a randomized 
controlled pilot study. Wien Klin Wochenschr 2005;117:761–8.
 11. Horne AW, Critchley HO, Doust A, et al. GaPP: a pilot randomised 
controlled trial of the efficacy of action of gabapentin for the 
management of chronic pelvic pain in women: study protocol. BMJ 
Open 2012;2:e001297.
 12. Lewis SC, Bhattacharya S, Wu O, et al. Gabapentin for the 
Management of Chronic Pelvic Pain in Women (GaPP1): A Pilot 
Randomised Controlled Trial. PLoS One 2016;11:e0153037.
 13. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: 
construction of scales and preliminary tests of reliability and validity. 
Med Care 1996;34:220–33.
 14. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain 
Inventory. Ann Acad Med Singapore 1994;23:129–38.
 15. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of 
fatigue severity in cancer patients: use of the Brief Fatigue Inventory. 
Cancer 1999;85:1186–96.
 16. Goldberg DP. Manual of the General Health Questionnaire. Windsor, 
England: NFER Publishing, 1978.
 17. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility 
of a work productivity and activity impairment instrument. 
Pharmacoeconomics 1993;4:353–65.
 18. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: 
Development and validation. Psychol Assess 1995;7:524–32.
 19. Thirlaway K, Fallowfield L, Cuzick J. The Sexual Activity 
Questionnaire: a measure of women’s sexual functioning. Qual Life 
Res 1996;5:81–90.
 20. Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new 
screening questionnaire to identify neuropathic components in 
patients with back pain. Curr Med Res Opin 2006;22:1911–20.
 21. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical 
importance of treatment outcomes in chronic pain clinical trials: 
IMMPACT recommendations. J Pain 2008;9:105–21.
 22. Grace VM. Problems women patients experience in the medical 
encounter for chronic pelvic pain: a New Zealand study. Health Care 
Women Int 1995;16:509–19.
 23. Brawn J, Morotti M, Zondervan KT, et al. Central changes associated 
with chronic pelvic pain and endometriosis. Hum Reprod Update 
2014;20:737–47.
 24. Kaya S, Hermans L, Willems T, et al. Central sensitization in 
urogynecological chronic pelvic pain: a systematic literature review. 
Pain Physician 2013;16:291–308.
 25. Whitaker LH, Reid J, Choa A, et al. An Exploratory Study into 
Objective and Reported Characteristics of Neuropathic Pain in 
Women with Chronic Pelvic Pain. PLoS One 2016;11:e0151950.
 26. Neuropathic pain in adults: pharmacological management in non-
specialist settings NICE Clinical Guideline. BMJ 2013;340:707–9.
 27. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures 
for chronic pain clinical trials: IMMPACT recommendations. Pain 
2005;113:9–19.
 28. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design 
considerations for confirmatory chronic pain clinical trials: IMMPACT 
recommendations. Pain 2010;149:177–93.
group.bmj.com on February 23, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
women: study protocol
management of chronic pelvic pain in
trial of the efficacy of gabapentin for the 
GaPP2, a multicentre randomised controlled
de C Williams and Andrew W Horne
Macfarlane, Lee Middleton, Wojciech Szubert, Irene Tracey, Amanda C
Ying Cheong, Roman Cregg, Jane Daniels, Catherine A Hewitt, Gary J 
Katy Vincent, Andrew Baranowski, Siladitya Bhattacharya, Judy Birch,
doi: 10.1136/bmjopen-2016-014924
2018 8: BMJ Open
 http://bmjopen.bmj.com/content/8/1/e014924
Updated information and services can be found at: 
These include:
References
 http://bmjopen.bmj.com/content/8/1/e014924#ref-list-1
This article cites 26 articles, 3 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on February 23, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
